Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7264 in Refractory or Unexplained Chronic Cough (Phase 3, China)
CTR20182515Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefapixant in refractory chronic cough (RCC), chronic idiopathic cough (CIC), sponsored by Merck & Co.. Started Jan 2019; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on CTR20182515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182515.